NIRSEVIMAB has been approved by the US FDA as the first RSV prevention measure for all infant populations
The US Food and Drug Administration (FDA) has announced the approval of a monoclonal antibody nirsevimab for the prevention of respiratory syncytial virus (RSV) related lower respiratory diseases in all infant populations.The FDA approves nirsevimab for the prevention of lower respiratory tract diseases caused by RSV in infants and young children: newborns and infants who are about to enter or are born during the first RSV infection season, as well as children who are still susceptible to severe RSV diseases within 24 months of age during the second RSV infection season...